Health experts expressing their views on causes of heart diseases and its treatment in Mandi.

NUS Medicine
8 followers
1 Video View·Dec 2, 2024
Rheumatic fever, rheumatic heart disease, as you know, is basically a disease of poverty.
It's not a regulated field to do research, do interventions.
Of course, it has an important impact on the public health
and basically affects the low and middle income countries
and people who have low Human Development Index.
If you see the distribution of burden of rheumatic fever, rheumatic heart disease,
it's more prevalent in low and middle income countries like South Asians, African countries, South America,
Pacific Islanders, those who are indigenous population in Australia and New Zealand.
So, should I continue without seeing it, right?
Kunal, how much time are you going to take?
It should be done in the next few minutes.
So, basically, I will take the floor because the slide gets ready.
When we started this registry in our department,
at that point of time, we did not have any data related to demographic characteristics of the patients,
clinical characteristics of the patients,
what proportion of patients have resided in the nursing care center with advanced complications
and what is the natural progression of rheumatic heart disease.
And these were some of the areas where we did not have any information about the heart patient population.
If you see the Indian scenario also, we do not have any data,
no data of the patients with rheumatic heart disease,
where we have followed the patients annually and assessed,
recorded the clinical outcomes, like for example,
the mortality because of the rheumatic heart disease
and the incidence of various complications like atrial fibrillation, heart failure,
strokes and proportion of patients requiring interventions
and complications in the form of infective metabolitis and recurrence of rheumatic fever.
So, and what happens to the progression of the disease?
Basically, with the passage of time, what is the proportion of patients?
So, progression of the disease, what is the proportion of patients?
So, regression of the disease.
These were some of the important information which we were lacking.
And so, with this in mind, we had started our registry which I am going to share.
We might like to start with this,
except for lower high-risk patients,
there are two areas where you have to be careful.
So, these are the various groups,
A and B,
and this is the general categorization,
and there are the various groups.
You always start with high-risk patients,
and then high-risk patients.
Subsequently, we have the clear outcome data,
where it is shown that it reduces amazing rates.
So, you can add,
and then there is the SIR.
Again, if you start with oily type,
it does reduce slowly.
And lastly, if it reduces,
there is also a reduction in stroke.
And, for only the first few days, you get stroke prevention also.
So, the idea is simple.
Calculate your risk category,
calculate your goal,
and then the expected goals,
which will lead to an expected reduction in the area,
which will achieve the highest level of risk.
So, you should go to the NLA recommendation,
which you can go and confront this.
Primary prevention studies have clearly shown that
stroke prevention is almost 100% balanced,
slightly lesser.
Aggressive ideal lowering with high risk of scatting
is important for primary prevention,
and secondary prevention,
so there is markedly improved stroke.
Very low ideal levels are not associated with high-risk risk.
We have seen this in almost 50,000 patients
that are from the improved variety of oral embolism.
Even the acquisition of stroke,
after thrombolysis or before thrombolysis,
you can extract scatting.
In ICS patients, first the patient is stabilized,
and then before discharge,
calculate his risk category and minimum scatting.
